...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dermatologic surgery >Perioperative management of anticoagulant therapy during cutaneous surgery: 2005 survey of Mohs surgeons.
【24h】

Perioperative management of anticoagulant therapy during cutaneous surgery: 2005 survey of Mohs surgeons.

机译：皮肤手术期间抗凝治疗的围手术期管理：2005年莫氏外科医师调查。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: The perioperative management of anticoagulation and antiplatelet therapy is a controversial topic in the field of dermatologic surgery. Dermasurgeons must weigh the risk of bleeding against the risk of thrombotic complications when deciding how to manage perioperative anticoagulation. OBJECTIVE: Our aim is to present a summary of current practice in anticoagulation management perioperatively during cutaneous surgery. We compare our results to those found in a similar survey in 2002. METHODS AND MATERIALS: A questionnaire surveying current practice in perioperative management of anticoagulant therapy was mailed to 720 dermasurgeons. RESULTS: Thirty-eight percent of dermasurgeons responded to the questionnaire. Of the responding physicians, 87% discontinue prophylactic aspirin therapy, 37% discontinue medically necessary aspirin, 44% discontinue warfarin, 77% discontinue nonsteroidal anti-inflammatory drugs (NSAIDs), and 77% discontinue vitamin E therapy perioperatively at least some of the time. Although clopidogrel was not surveyed, 78 physicians included comments about the management of this agent. CONCLUSION: Dermasurgeons were more likely to continue medically necessary aspirin and warfarin in 2005 compared to 2002, with the most dramatic shift evident in the management of warfarin. They were more likely to discontinue prophylactic aspirin, NSAIDs, and vitamin E. Surgeons were concerned about bleeding with the antiplatelet agent clopidogrel. More evidence-based medicine is necessary to set guidelines for the management of anticoagulation and antiplatelet therapy perioperatively.
机译：背景：抗凝和抗血小板治疗的围手术期管理在皮肤外科领域是一个有争议的话题。在决定如何管理围手术期抗凝治疗时，皮肤外科医生必须权衡出血风险与血栓并发症的风险。目的：我们的目的是总结皮肤手术围手术期抗凝治疗的当前实践总结。我们将我们的结果与2002年类似调查中的结果进行比较。方法和材料：720名皮肤科医生邮寄了一份问卷，调查了围手术期抗凝治疗的当前实践。结果：38％的皮肤科医生回答了问卷。在做出回应的医生中，至少在某些时候，围手术期中断了87％的患者停用预防性阿司匹林治疗，37％的患者停止了医学上必要的阿司匹林治疗，44％的患者停用了华法林，77％的患者停用了非甾体抗炎药（NSAIDs）和77％的患者停止了维生素E治疗。尽管未调查氯吡格雷，但有78位医生对这种药物的治疗发表了评论。结论：与2002年相比，2005年皮肤外科医生更有可能继续在医学上使用阿司匹林和华法林，其中最明显的变化是华法林的治疗。他们更有可能停用预防性阿司匹林，非甾体抗炎药和维生素E。外科医生担心使用抗血小板药物氯吡格雷会出血。需要更多的循证医学来为围手术期抗凝和抗血小板治疗的管理制定指南。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号